Drug does not increase suitability for dialysis of surgically-enlarged blood vessels

The anti-platelet drug clopidogrel reduced the frequency of early blood clot formation in new surgically enlarged blood vessels (fistulas) created for patients requiring dialysis, but did not increase the proportion of these fistulas that subsequently became suitable for use during dialysis, according to a study in the May 14 issue of JAMA.

“Approximately 470,000 Americans have end-stage renal disease, and most are treated with hemodialysis. A major challenge in caring for patients undergoing hemodialysis is maintaining a functioning vascular access, which is essential for performing the dialysis procedure. The effect of vascular access dysfunction is substantial—it is a leading reason for hospitalization among patients with end-stage renal disease and has associated annual costs in the United States that exceed $1 billion,” the authors write.

The preferred type of hemodialysis vascular access is an arteriovenous fistula, created by surgically connecting an artery and a vein. This arterio-venous connection and the resulting increase in the blood flow through the vein cause its diameter to increase, enabling the typically thrice weekly vein puncture necessary for administering dialysis. The fistula is preferred over other types of hemodialysis vascular access such as synthetic arteriovenous grafts because of lower rates of blood clot formation (thrombosis) and infection as well as reduced access-related and total health care expenditures. Offsetting these advantages is the substantially higher proportion of fistulas than grafts that are never able to be used for dialysis because of failure to mature adequately to support effective hemodialysis, according to background information in the article. Some small trials have suggested that anti-platelet drugs may reduce thrombosis of new fistulas.

The Dialysis Access Consortium, including Laura M. Dember, M.D., of the Boston University School of Medicine, and colleagues performed a multicenter, randomized, placebo-controlled trial to determine whether clopidogrel reduces early failure of hemodialysis fistulas. The study included 877 participants with end-stage renal disease or advanced chronic kidney disease who underwent surgical creation of a fistula. Participants were randomly assigned to receive clopidogrel (n = 441) or placebo (n = 436) for 6 weeks starting within 1 day after fistula creation.

The researchers found that participants in the clopidogrel group had a 37 percent lower risk of fistula thrombosis at 6 weeks compared to participants in the placebo group. Among the 866 participants who had fistula patency (lack of obstruction) assessed, 53 participants (12.2 percent) in the clopidogrel group experienced fistula thrombosis, compared to 84 participants (19.5 percent) in the placebo group.

However, among the 86 percent of fistulas assessed for suitability for use during dialysis, the percentage with suitability failure was high and did not differ between the clopidogrel group and the placebo group (61.8 percent vs. 59.5 percent, respectively).

“In conclusion, clopidogrel reduces the incidence of early thrombosis of new arteriovenous fistulas but does not increase the proportion that become suitable for dialysis. The high rate of fistula suitability failure observed in this large trial conducted at centers with a particular interest in hemodialysis vascular access provides a compelling argument for additional efforts to identify mechanisms underlying fistula maturation failure, criteria for selecting suitable candidates for fistula creation, and interventions to enhance fistula maturation,” the authors write.

Citation: JAMA. 2008;299[18]:2164-2171.

Source: JAMA and Archives Journals

Related stories:

Reducing blockage fails to improve access to the bloodstream for kidney dialysis
Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.
Robotic device appears useful for surgical removal of cancer involving the tonsils
A new robotic surgery technique appears promising for the removal of cancer involving the tonsil region, according to a report in the December issue of Archives of Otolaryngology–Head & Neck Surgery, one of the JAMA/Archives journals.
Crohn's disease surgeries make steady advances
Thousands of Americans suffering from the chronic inflammatory bowel condition known as Crohn's disease are leading longer, healthier lives due to innovative new surgeries, according to experts at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Urologists report success using robot-assisted surgery for urinary abnormality
Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.
How to effectively avoid many common complications and liver damage in bile duct exploration?
Micro-wound operation is becoming the trend in surgery in the 21st century and laparoscopic surgery is regarded as an important component of micro-wound surgery.
A strange case of upper obstructive syndrome
Aorto-duodenal fistulae (ADF) are the most frequent aorto-enteric fistulae (80%) and the most frequent presenting sign of ADF is upper gastrointestinal bleeding (UGI). A 59-year-old male patient, who underwent an aortic-bi-femoral bypass five years ago, was admitted to the Emergency Room after five days of persistent occlusive syndrome with dyspepsia and biliary vomiting.
Asian women at risk for arterial defect
A seemingly random arterial abnormality that can cause heart attack and sudden death in adults with no previous symptoms may not be so random after all. A group of researchers in the Netherlands discovered that many people with congenital aneurismal fistulas share traits that may help doctors prevent attacks by identifying and treating patients at risk. They reported their findings in Congenital Heart Disease.
Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
Researchers from Mayo Clinic in Rochester, Minnesota, recently examined the use of self-expanding plastic stents (SEPSs) in the treatment of benign esophageal disease and found that use of SEPSs resulted in frequent stent migration and few cases of long-term improvement. They concluded that further investigation is warranted to identify optimal patient populations and to guide future recommendations for the use of SEPSs. The study appears in the January issue of Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

News discussion:

Medicine & Health news